^
    19d
    Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma. (PubMed, J Immunother Cancer)
    Our findings highlight a central role for B cells and TLSs in shaping the immune microenvironment of NB. Their presence and maturation status are linked to clinical outcome, suggesting their potential as prognostic biomarkers and targets for novel immunotherapeutic strategies in pediatric oncology.
    Journal • IO biomarker
    |
    nCounter® PanCancer Immune Profiling Panel
    2ms
    Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background. (PubMed, Cancers (Basel))
    These findings support a post-germinal center origin for EBL, which arises in a background of chronic inflammation and persistent antigen stimulation.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    nCounter® PanCancer Immune Profiling Panel
    3ms
    Differential expression profiles of immunoregulatory genes in anaplastic thyroid carcinomas with a coexistent papillary carcinoma component. (PubMed, Virchows Arch)
    In conclusion, ATC displays high levels of expression of immunoregulatory genes as compared to PDTC. Moreover, a subset of genes and miRNAs is significantly de-regulated along progression from PTC to ATC, suggesting their potential role as biomarkers and involvement in key functional mechanisms.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • RIPK2 (Receptor Interacting Serine/Threonine Kinase 2) • BLNK (B Cell Linker) • ITGA5 (Integrin Subunit Alpha 5) • ITGB1 (Integrin Subunit Beta 1)
    |
    nCounter® PanCancer Immune Profiling Panel
    4ms
    Gene expression and molecular pathway analyses differentiate immunotherapy-induced myositis from spontaneous dermatomyositis. (PubMed, Sci Rep)
    The gene expression correlation and putative molecular interactions set irMyositis apart from DM, particularly with respect to IFN response and DGE of interactors of ICI protein targets (CTLA4, PD-1, PD-L1). Our results suggest new avenues for understanding immunotherapy-related adverse events.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3)
    |
    nCounter® PanCancer Immune Profiling Panel
    5ms
    Cancer Testis Antigen Expression Correlates With Immune Activation and Survival in Small Bowel Neuroendocrine Tumors. (PubMed, JCO Precis Oncol)
    High CTA expression in resected SBNET is independently associated with improved survival. Epigenetic dysregulation and immune activation in CTA-enriched tumor regions highlight the potential for combination epigenetic modifiers and immunotherapy in future trials.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    12ms
    BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression. (PubMed, Front Endocrinol (Lausanne))
    BRAFmutpTERTwt had higher stromal lymphocytes infiltration as compared to BRAFwtpTERTwt tumors, corroborating the transcriptomic findings. To our knowledge this is the first report of a potential link between TERT and the immune microenvironment, offering an explanation for the aggressive nature of BRAFmutpTERTmut PTC.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF V600E • BRAF V600 • TERT mutation • TERT promoter mutation
    |
    nCounter® PanCancer Immune Profiling Panel
    12ms
    Transcriptomic Profiling Reveals Key Biomarkers in Primary Refractory and Early Relapse Classical Hodgkin Lymphoma (ASH 2024)
    Furthermore, increased activity of macrophages and reduced expression of B-cells support previous studies underlining their involvement in treatment resistance. Despite limitations in sample size, these findings shed light on the mechanisms behind resistance and early relapse in cHL, which could help guide the development of targeted therapies and potentially improve early risk assessment.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • CD68 (CD68 Molecule) • CD79A (CD79a Molecule) • CSF1R (Colony stimulating factor 1 receptor) • CCL3 (C-C Motif Chemokine Ligand 3) • MS4A1 (Membrane Spanning 4-Domains A1) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • BLNK (B Cell Linker) • C1QB (Complement C1q B Chain) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • TLR2 (Toll Like Receptor 2)
    |
    PD-L1 expression • CD22 expression
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    Gene Expression Profiling of the Peritumoral Immune Cell Infiltrate of Penile Squamous Cell Carcinomas. (PubMed, Int J Mol Sci)
    Among these cases, the genes GZMA, MICB, and GNLY were significantly upregulated, suggesting their involvement in an increased immune response. The role of HPV infection status in our cases with regard to the peritumoral immune cell infiltrate remains inconclusive.
    Journal • Immune cell
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • IRF4 (Interferon regulatory factor 4) • GZMA (Granzyme A) • MICB (MHC Class I Polypeptide-Related Sequence B)
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse (ASH 2024)
    Low T cell diversity is a marker of poor overall survival at relapse. These findings suggest T cell mediated immunity is critical for chemotherapy response in DLBCL and could have implications for predicting responses to newer T cell directed therapies such as bispecific T cell and CART therapies.
    PD(L)-1 Biomarker • IO biomarker • Biopsy
    |
    CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD68 (CD68 Molecule) • CD7 (CD7 Molecule) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • RELA (RELA Proto-Oncogene) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    Elevated Cancer Testis Antigen Expression Corresponds to Immune Activation and Improved Survival in Small Bowel Neuroendocrine Tumors (NANETS 2024)
    Augmentation of the peritumoral immune environment in CTAhigh regions suggests a role for CTA expression in modulating tumor response. Targeted pathways to drive CTA expression may represent an opportunity to improve tumor sensitivity and response to immunotherapy in future trials.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • KDM6A (Lysine Demethylase 6A) • CD27 (CD27 Molecule) • WDR5 (WD Repeat Domain 5)
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    GENE EXPRESSION SIGNATURE REVEALS A PROTECTIVE ROLE OF B-CELLS IN THE PROGRESSION OF CLASSICAL HODGKIN LYMPHOMA PATIENTS (ISHL 2024)
    These results suggest gene expression analysis could aid in early relapse detection and underscore the immune-modulatory role of B-cells in cHL progression.
    Clinical
    |
    PAX5 (Paired Box 5)
    |
    7-gene signature
    |
    nCounter® PanCancer Immune Profiling Panel
    1year
    TFAP2A-activated ITGB4 promotes lung adenocarcinoma progression and inhibits CD4+/CD8+ T-cell infiltrations by targeting NF-κB signaling pathway. (PubMed, Transl Lung Cancer Res)
    ITGB4 was transcriptionally activated by TFAP2A, and could promote LUAD progression and inhibit CD4+/CD8+ T-cell infiltrations by activating the NF-κB signaling pathway. ITGB4 may serve as a potential immunotherapeutic target of LUAD.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NFKBIA (NFKB Inhibitor Alpha 2) • ITGB4 (Integrin Subunit Beta 4) • TFAP2A (Transcription Factor AP-2 Alpha)
    |
    nCounter® PanCancer Immune Profiling Panel